26 Dec, 09:34 - Indian

SENSEX 78792.75 (0.41)

Nifty 50 23816.25 (0.37)

Nifty Bank 51597 (0.71)

Nifty IT 43651.1015625 (-0.04)

Nifty Midcap 100 56942.1484375 (-0.20)

Nifty Next 50 68957 (0.14)

Nifty Pharma 22475.19921875 (-0.37)

Nifty Smallcap 100 18705.5 (-0.14)

26 Dec, 09:34 - Global

NIKKEI 225 39482.49 (0.90)

HANG SENG 20098.29 (1.08)

S&P 6115.75 (0.09)

Login/Signup
LOGIN HERE
Cancel

Medico Remedies Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 540937 | NSE Symbol : MEDICO | ISIN : INE630Y01024 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
06-Nov-2024 12-Nov-2024 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended 30th September 2024 along with the Limited Review Report thereon Outcome of Board Meeting held today Please find attached Outcome of Board Meeting held today (As Per BSE Announcement Dated on 12.11.2024)
05-Aug-2024 12-Aug-2024 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve 1. Unaudited Financial Results for the quarter ended 30th June 2024 along with the Limited Review Report thereon; 2. Any other business with the permission of the Chair. Financial Results for Quarter ended June, 2024 (As Per BSE Announcement dated on 12.08.2024)
30-Apr-2024 09-May-2024 Accounts Audited Results Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today ie. 9th May, 2024 has, inter alia considered and approved the following: 1. Audited Standalone Financial Results of the Company for the quarter ended 31 March, 2024 and Audited Financial Statements for the year ended on 31st March, 2024 along with the Auditor's Report thereon. 2. Board's Report and its annexures, Management Discussion Analysis (MDA) and Corporate Governance Report of the Company for the financial year ended on 31st March, 2024. Please find attached Audited Standalone Financial Results for quarter and year ended 31st March, 2024. (As Per BSE Announcement Dated on 09/05/2024)
30-Jan-2024 12-Feb-2024 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve Unaudited Financial Results for the Quarter and Nine months ended 31st December 2023 along with the Limited Review Report thereon Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 12 February, 2024 has, inter alia considered and approved the Quarterly Unaudited Standalone Financial Results of the Company for the Quarter and Nine Months ended 31*'' December, 2023 along with the Limited Review Report thereon. (enclosed) Unaudited Financial Results for quarter and nine months ended 31st December, 2023 (As Per BSE Announcement Dated on 12/02/2024)
31-Oct-2023 09-Nov-2023 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended 30th September 2023 along with the Limited Review Report thereon Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors at their Meeting held today i.e. 9' November, 2023 has, inter alia considered and approved the Unaudited Financial Results for the quarter and half year ended 30' September, 2023 alongwith Auditors' Limited Review Report thereon. We wish to inform you that the Board Meeting commenced today at 3.00 P.M and concluded at 5.10 P.M Please find attached Unaudited Financial Results for the quarter and half year ended 30th September, 2023 approved at Board meeting held today. (As per BSE Announcement Dated on 09/11/2023)
01-Aug-2023 10-Aug-2023 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve Unaudited Financial Results for the quarter ended 30th June 2023 along with the Limited Review Report thereon Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 10th August, 2023 has, inter alia considered and approved the Quarterly Unaudited Standalone Financial Results of the Company for the quarter ended 30th June, 2023 along with the Limited Review Report thereon. (As Per BSE Announcement dated on 10.08.2023)
20-Jul-2023 20-Jul-2023 AGM The Board of Directors at its meeting held today has approved the following: 1. Notice of the 29th Annual General Meeting of the Company; 2. Re-appointment of Mr. Haresh Mehta (DIN: 01080289) as Chairman & Whole-Time Director of the Company for a further period of three years w.e.f. 17th September, 2023 to 17th September, 2026 subject to approval of members; 3. Re-apppointment of Mr. Rishit Mehta (DIN: 07121224) as Whole-Time Director of the Company for a further period of three years w.e.f. 17th September, 2023 to 17th September, 2026 subject to approval of members and 4. Appointment of Mr. Haresh Sanghvi, Practicing Company Secretary as Secretarial Auditor of the Company to conduct Secretarial Audit for Financial Year 2023-24. The Board of Directors at their meeting held today approved the following: 1. Notice of the 29th Annual General Meeting of the Company; 2. Re-appointment of Mr. Haresh Mehta as Chairman & Whole-Time Director of the Company for a further period of three years subject to the approval of members; 3. Re-appointment of Mr. Rishit Mehta as Whole-Time Director of the Company for a further period of three years subject to the approval of the members and 4. Appointment of Mr. Haresh Sanghvi, Practicing Company Secretary as Secretarial Auditor of the Company to conduct Secretarial Audit for the Financial Year 2023-24.
03-May-2023 11-May-2023 Accounts Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2023 inter alia to consider and approve 1. Audited Financial Results for the half year ended 31st March 2023 and Audited Financial Statements for the year ended on 31st March 2023 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 11th May, 2023 has, inter alia considered and approved the following: 1. Audited Standalone Financial Results of the Company for the quarter ended 31st March, 2023 and Audited Financial Statement for the year ended on 31st March, 2023 along with the Auditor's Report thereon. 2. The Board's Report and its annexures, Management Discussion Analysis (MDA) and Corporate Governance Report of the Company for the financial year ended on 31st March, 2023. (As per BSE Announcement Dated on 11/05/2023)
02-Feb-2023 10-Feb-2023 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve 1. Unaudited Financial Results for the Quarter and Nine months ended 31st December 2022 along with the Limited Review Report thereon; 2. Any other business with the permission of the Chair. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 10th February, 2023 has, inter alia considered and approved the Quarterly Unaudited Standalone Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2022 along with the Limited Review Report thereon. (enclosed) We wish to inform you that the Board Meeting commenced today at 2.00 P.M and concluded at 5: 15 P.M Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 10th February, 2023 has, inter alia considered and approved the Quarterly Unaudited Standalone Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2022 along with the Limited Review Report thereon. (enclosed) (As Per BSE Announcement dated on 10.02.2023)
13-Jan-2023 02-Feb-2023 Stock Split Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2023 inter alia to consider and approve Pursuant to Regulation 29(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday 2nd February 2023 inter alia to consider and approve: 1. Sub-division/ Stock Split of equity shares of the Company. 2. Any other matter with the permission of the Chair. Medico Remedies Limited has informed the Exchange that the Board of Directors at its meeting held on February 02, 2023, has considered and approved subdivision of 16596800 equity shares of 10 each into 82984000 equity shares of 2 each. (As Per NSE Announcement Dated on 02/02/2023) Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 2nd February, 2023 has, inter alia considered and approved the following: 1. Sub-division/ Stock Split of equity shares of the Company 2. Notice of Postal Ballot The Board of Directors of the Company at its Meeting held today, subject to approval of the shareholders, to be obtained by means of Postal Ballot has resolved to amend Clause V (Capital Clause) of the Memorandum of Association of the Company (As Per BSE Announcement Dated on 02.02.2023)
04-Nov-2022 12-Nov-2022 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve 1. Unaudited Financial Results for the quarter and half year ended 30th September 2022 along with the Limited Review Report thereon; 2. Any other business with the permission of the Chair. In compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the newspaper advertisements published in 'Active Times' (English Edition) and in 'Pratahkal' (Marathi Edition) on 14th November, 2022 for announcement of Unaudited Financial Results for the quarter and half year ended 30th September, 2022. (As Per BSE Announcement Dated on 14.11.2022)
04-Aug-2022 12-Aug-2022 Quarterly Results Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 inter alia to consider and approve 1. Unaudited Financial Results for the quarter ended 30th June 2022 along with the Limited Review Report thereon 2. Any other business with the permission of the Chair Medico Remedies Limited has informed the Exchange about Board Meeting held on 12-Aug-2022 to consider financial statements for the period ended June 2022 and Other business matters (As per BSE Announcement Dated on 12/08/2022)
12-May-2022 20-May-2022 Accounts Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2022 inter alia to consider and approve 1.To consider and approve Audited Financial Results for the half year ended 31st March 2022 and Audited Financial Statements for the year ended on 31st March 2022; and 2. Any other business with the permission of the Chair we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 20th May, 2022 has, inter alia considered and approved the following: 1. Audited Standalone Financial Results of the Company for the half-year ended 31st March, 2022 and Audited Financial Statement for the year ended on 31st March, 2022 along with the Auditor's Report thereon. 2. Reappointment of Mr. Harshit Mehta as a Managing Director for a term of three consecutive years 3. Reappointment of Mr. Ramesh Rughani as an Independent Director for a second term of five consecutive years 4. Reappointment of Mr. Deepak Vekaria as an Independent Director for a second term of five consecutive years 5. Reappointment of Mr. Bharat Rathod as an Independent Director for a second term of five consecutive years 6. Increase in the borrowings limit of the Company 7. Creation of Mortgage/Charge on the Assets of the Company 8. Notice of Postal Ballot Audited Standalone Financial Results of the Company for the half-year ended 31st March, 2022 and Audited Financial Statement for the year ended on 31st March, 2022 along with the Auditor's Report thereon (As Per BSE Announcement Dated on 20.05.2022)
03-Nov-2021 12-Nov-2021 Half Yearly Results Half Yearly Results Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors at their Meeting held today i.e. 12th November, 2021 has, inter alia considered and approved the Unaudited Financial Results for the half year ended 30th September, 2021 alongwith Auditors' Limited Review Report thereon (As per BSE Announcement Dated on 12/11/2021)
30-Sep-2021 07-Oct-2021 Increase in Authorised Capital Increase in Authorised Capital & Bonus issue Inter alia, to transact the following business: 1. To consider increase in authorized share capital of the Company and subsequent alteration to the Memorandum of Association of the Company; 2. To recommend and approve issue of Bonus shares to the equity shareholders of the Company; 3. To approve the proposal of Migration of Company from SME platform of BSE to Main Board of BSE Limited as well as on the Main Board of NSE Limited; 4. To approve the transactions to be entered into with the related parties of the Company; and 5. Any other business with the permission of the Chair. The Board of Directors at their Meeting held today i.e. 7th October, 2021 has, inter alia considered and approved the following: 1. Increase in Authorized Share Capital of the Company from ? 4,50,00,000 divided into 45,00,000 Equity Shares of ? 10/- each to ? 17,00,00,000 divided into 17,00,000 Equity Shares Equity Shares of ? 10/- each and subsequent alteration to the Memorandum of Association of the Company, 2. Issue of Bonus shares in the ratio of 3:1 (3 (three) fully paid-up equity shares for every 1 (One) existing fully paid-up equity share held by the shareholders), 3. Migration of Listing/Trading of Company''s present listing from SME Platform of BSE Limited to the Main Board of BSE Limited as well as on Main Board of NSE Limited 4. Transactions to be entered into with the related parties of the Company; 5. Approval of Postal Ballot Notice; and 6. Appointment of Scrutiniser for scrutinising the Postal Ballot process in a fair and transparent manner. (As Per BSE Announcement Dated on 07.10.2021)
1 2